Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 11 to 14 amino acid residues in defined sequence
Reexamination Certificate
2011-08-02
2011-08-02
Audet, Maury (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
11 to 14 amino acid residues in defined sequence
C514S001100, C424S001690
Reexamination Certificate
active
07989589
ABSTRACT:
Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed.
REFERENCES:
patent: 4299838 (1981-11-01), Durlach
patent: 4576750 (1986-03-01), Pitzenberger
patent: 4870097 (1989-09-01), Makovec et al.
patent: 5167960 (1992-12-01), Ito et al.
patent: 5256642 (1993-10-01), Fearon et al.
patent: 5776970 (1998-07-01), Shechter et al.
patent: 6169057 (2001-01-01), Lovatt
patent: 6214790 (2001-04-01), Richelson et al.
patent: 6319897 (2001-11-01), Lambris et al.
patent: 2001/0023066 (2001-09-01), Kinders et al.
patent: WO 91/16345 (1991-10-01), None
patent: WO 95/23512 (1995-08-01), None
patent: WO 99/13899 (1999-03-01), None
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”,Science247:1306-1310 (1990).
Fiane, et al., “Prolongation of Ex Vivo-Perfused Pig Xenograft Survival by the Complement Inhibitor Compstatin”,Transplantation Proceedings31:934-935 (1999).
Fiane, et al. “Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts”,Xenotransplatation6: 52-65 (1999).
Fiane, et al., “Modulation of Fluid-Phase Complement Activation Inhibits Hyperacute Rejection in a Porcine-to-Human Xenograft Model”,Transplantation Proceedings32:899-900 (2000).
Furlong, et al., “C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl α-ketoheterocycles”,Immunopharmacology48:199-212 (2000).
Kalli, et al., “Therapeutic uses of recombinant complement protein inhibitors”,Springer Seminars in Immunopathology15:417-431 (1994).
Klepeis, et al., “Predicting Peptide Structures Using NMR Data and Deterministic Global Optimization”,Journal of Computational Chemistry20 (13):1354-1370 (1999).
Klepeis, et al., Integrated Computational Experimental Approach for Lead Optimization and Design of Compstatin Variants with Improved Activity,J. Am. Chem. Soc.125:8422-8423 (2003).
Mallik, et al., “Conformational Interconversion in Compstatin Probed With Molecular Dynamics Simulations”,Proteins: Structure, Function, and Genetics52:130-141 (2003).
Morikis, et al., “Solution structure of Compstatin, a potent complement inhibitor”,Protein Science7:6190-627 (1998).
Morikis, et al., “Design, Structure, Function and Application of Compstatin”,Bioactive Peptides in Drug Discovery and Design: Medical Aspects, J. Matsoukas and T. Mavromoustakos (Eds) IOS Press, pp. 235-246 (1999).
Morikis, et al., “The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR”,The Journal of Biological Chemistry277 (17):14942-14953 (2002).
Morikis, et al., “Structural aspects and design of low-molecular-mass complement inhibitors”,Biochemical Society Transactions30 (6):1026-1036 (2002).
Nilsson, et al., “Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation”,Blood92 (5):1661-1667 (1998).
Ngo, et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”,The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495 (1994).
Sahu, et al., “Inhibition of Human Complement by a C3-Binding Peptide Isolated from a Phage-Displayed Random Peptide Library”,Journal of Immunology157:884-891 (1996).
Sahu, et al., “Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin”,The Journal of Immunology165:2491-2499 (2000).
Sahu, et al., “Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3”,Molecular Immunology39:557-566 (2003).
Schasteen, et al., “Synthetic Peptide Inhibitors of Complement Serine Proteases-III. Significant Increase in Inhibitor Potency Provides Further Support for the Functional Equivalence Hypothesis”,Molecular Immunology28 (1/2):17-26 (1991).
Soulika, et al., “Inhibition of Heparin/Protamine Complex-Induced Complement Activation by Compstatin in Baboons”,Clinical Immunology96 (3):212-221 (2000).
Soulika, et al., “Studies of Structure-Activity Relations of Complement Inhibitor Compstatin”,The Journal of Immunology170:1881-1890 (2003).
Zacharias, et al., “Cation-π interactions in ligand recognition and catalysis”,Trends in Pharmacological Sciences23 (6):281-287 (2002).
Babitzke, et al., “Structural Features ofL-Tryptophan Required for Activation of TRAP, thetrpRNA-binding Attenuation Protein ofBacillus subtilis”, 270 (21):12452-12456 (1995).
Beene, et al., “Cation-π Interactions in Ligand Recognition by Serotonergic (5-HT3A) and Nicotinic Acetylcholine Receptors: The Anomalous Binding Properties of Nicotine”,Biochemistry41:10262-10269 (2002).
Beeley, N., “Pedidomimetrics and small-molecular drug design: towards improved bioavailability and in vivo stability”, Trends Biotechnol., vol. 12, pp. 213-216 (1994).
Dennis, M.S., et al., “Albumin binding as a general strategy for improving pharmacokinetics of proteins”, J. Biol. Chem., vol. 277, pp. 35035-35043 (2002).
Hruby, V.J., “Conformational and topographical considerations in the design of biologically active peptides”, Biopolymers, vol. 33, pp. 1073-1082 (1993).
Kozlowski, A., et al., “Development of pegylated interferons for the treatment of chronic hepatitis”, BioDrugs, vol. 15, pp. 419-429 (2001).
Spruce, L., et al., “Chemical synthesis of small complement proteins and protein modules”, International immunopharmacology, vol. 2, pp. 1320-1321 (2002).
Veronese, F.M., “Peptide and protein PEGylation: a review of problems and solutions”, Biomaterials, vol. 22, pp. 405-417 (2001).
Wang, Y., et al., “Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a . . .”, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 8563-8568 (1996).
Zhao, B., et al., “A paradigm for drug discovery using a conformation from the crystal structure of a presentation scaffold”, Nat. Struct. Biol., vol. 2, pp. 1131-1137 (1995).
Non-Final Office Action in U.S. Appl. No. 11/605,182, mailed Jun. 30, 2009.
Final Office Action in U.S. Appl. No. 11/605,182, mailed Mar. 3, 2010.
Notice of Allowance in U.S. Appl. No. 11/605,182, mailed Sep. 27, 2010.
Audet Maury
Potter Anderson & Corroon LLP
The Trustees of the University of Pennsylvania
LandOfFree
Compstatin analogs with improved activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compstatin analogs with improved activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compstatin analogs with improved activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663128